Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Jazz Pharmaceuticals plcJAZZ · Entity 818 | EVP, Chief Commercial Officer | August 05, 2026 | August 07, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Jazz Pharmaceuticals plc
Report date August 05, 2026 · Filed August 07, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 47,131 |
Reported balance
After 2026-08-05 transaction · row 1
1 source rowRow 1 · 2026-08-05 · Tax withholding · Disposed 780 · Balance 47,131 F1: Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 08, 2022 Filed Jun 10, 2022 21:24 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 2,652 | $155.00 | $411,060.00 |
DisclosureSEC source: 0001765581-22-000063 · edgardoc.xml · nonDerivative · entry 3 Pearce Samantha · CIK 0001805688 · SVP, Head of Europe & Internat 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,309 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| June 08, 2022 Filed Jun 10, 2022 21:24 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 5,835 | $155.00 | $904,425.00 |
DisclosureSEC source: 0001765581-22-000063 · edgardoc.xml · nonDerivative · entry 2 Pearce Samantha · CIK 0001805688 · SVP, Head of Europe & Internat 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,961 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| June 08, 2022 Filed Jun 10, 2022 21:24 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Exercise / conversionOrdinary Shares | 5,835 | $109.45 | $638,640.75 |
DisclosureSEC source: 0001765581-22-000063 · edgardoc.xml · nonDerivative · entry 1 Pearce Samantha · CIK 0001805688 · SVP, Head of Europe & Internat 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,796 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| March 05, 2022 Filed Mar 9, 2022 23:04 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Tax withholdingOrdinary Shares | 1,836 | $153.96 | $282,670.56 |
DisclosureSEC source: 0001765581-22-000026 · edgardoc.xml · nonDerivative · entry 2 Pearce Samantha · CIK 0001805688 · SVP, Head of Europe & Interna 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,961 F2 · kind: Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units. Read SEC document |
| March 03, 2022 Filed Mar 9, 2022 23:04 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantOrdinary Shares | 3,839 | $0.00 | $0.00 |
DisclosureSEC source: 0001765581-22-000026 · edgardoc.xml · nonDerivative · entry 1 Pearce Samantha · CIK 0001805688 · SVP, Head of Europe & Interna 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,797 F1 · kind: These restricted stock units are granted pursuant to the Issuer's 2011 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. These units vest in equal annual installments over four years measured from the vesting commencement date of March 5, 2022, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in equal annual installments over the subsequent three years. Read SEC document |
| March 05, 2021 Filed Mar 10, 2021 00:33 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Tax withholdingOrdinary Shares | 1,402 | $164.75 | $230,979.50 |
DisclosureSEC source: 0001765581-21-000040 · edgardoc.xml · nonDerivative · entry 1 Pearce Samantha · CIK 0001805688 · SVP, Head of Europe & Intl 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,958 F1 · kind: Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units. Read SEC document |
| February 25, 2021 Filed Mar 1, 2021 23:14 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantOrdinary Shares | 3,160 | $0.00 | $0.00 |
DisclosureSEC source: 0001765581-21-000026 · edgardoc.xml · nonDerivative · entry 1 Pearce Samantha · CIK 0001805688 · SVP, Head of Europe & Intl 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,360 F1 · kind: These restricted stock units are granted pursuant to the Issuer's 2011 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. These units vest in equal annual installments over four years measured from the vesting commencement date of March 5, 2021, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in equal annual installments over the subsequent three years. Read SEC document |
| May 07, 2020 Filed May 11, 2020 21:03 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 25,500 | $0.00 Strike: $109.45 | $0.00 |
DisclosureSEC source: 0001765581-20-000051 · edgardoc.xml · derivative · entry 2 Pearce Samantha · CIK 0001805688 · SVP, Europe and Rest of World 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,500 Underlying: Ordinary Shares · 25,500 shares Expires 2030-05-06 F2 · derivative.exercise_date: These options are granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vest over four years measured from the vesting commencement date of March 2, 2020, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in 36 equal monthly installments thereafter. Read SEC document |
| May 07, 2020 Filed May 11, 2020 21:03 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantOrdinary Shares | 10,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001765581-20-000051 · edgardoc.xml · nonDerivative · entry 1 Pearce Samantha · CIK 0001805688 · SVP, Europe and Rest of World 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,200 F1 · kind: These restricted stock units are granted pursuant to the Issuer's 2011 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. These units vest in equal annual installments over four years measured from the vesting commencement date of March 5, 2020, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in equal annual installments over the subsequent three years. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.